Clinical Trial

A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2025 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of this trial is to assess the post-infusion viability of INTERCEPT RBCs by measuring the 24-hour post-infusion recovery and lifespan of autologous RBCs prepared with the INTERCEPT Blood System for RBC with AS-1 after 35 days post collection storage in comparison to untreated AS-1 RBCs stored for 35 days.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-03; most recent amendment 2025-10-13.
Status change: Not Yet Recruiting → Recruiting 2025-10-13
Trial Details
NCT Number NCT07015437
Lead Sponsor Cerus Corporation
Conditions Healthy Subjects
Enrollment 70 participants
Start Date 2025-09-19
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-10-15 (estimated)
Updated on ClinicalTrials.gov 2025-10-15